The role of myeloid-derived suppressor cells in the pathogenesis of rheumatoid arthritis; anti- or pro-inflammatory cells?

References

• Kong YY, Fuchsberger M, Xiang SD, et al. Myeloid derived suppressor cells and their role in diseases. CMC. 2013;20(11):1437–1444.
   PubMed Web of Science ®Google Scholar
• Nagaraj S, Youn J-I, Gabrilovich DI. Reciprocal relationship between myeloid-derived suppressor cells and T cells. J Immunol. 2013;191(1):17–23.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253.
   PubMed Web of Science ®Google Scholar
• Solito S, Marigo I, Pinton L, et al. Myeloid‐derived suppressor cell heterogeneity in human cancers. Ann NY Acad Sci. 2014;1319(1):47–65.
   PubMed Web of Science ®Google Scholar
• Messmer MN, Netherby CS, Banik D, et al. Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy. Cancer Immunol Immunother. 2015;64(1):1–13.
   PubMed Web of Science ®Google Scholar
• Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell. 1996;85(3):307–389.
   PubMed Web of Science ®Google Scholar
• Gizinski AM, Fox DA. T cell subsets and their role in the pathogenesis of rheumatic disease. Curr Opin Rheumatol. 2014;26(2):204–210.
   PubMed Web of Science ®Google Scholar
• Lipsky PE, van der Heijde DM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343(22):1594–1602.
   PubMed Web of Science ®Google Scholar
• Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis. J Rheumatol. 2010;38(1):10–20.
   PubMed Web of Science ®Google Scholar
• Feldmann M, Maini RN. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med. 2003;9(10):1245.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Diaz-Lagares C, Cuadrado M-J, et al. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev. 2010;9(3):188–193.
   PubMed Web of Science ®Google Scholar
• Wang Y, Tian J, Wang S. The potential therapeutic role of myeloid-derived suppressor cells in autoimmune arthritis. Semin Arthritis Rheum. 2016;45(4):490–495.
   PubMed Web of Science ®Google Scholar
• Movahedi K, Guilliams M, Van den Bossche J, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell–suppressive activity. Blood. 2008;111(8):4233–4244.
   PubMed Web of Science ®Google Scholar
• Dumitru CA, Moses K, Trellakis S, et al. Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol Immunother. 2012;61(8):1155–1167.
   PubMed Web of Science ®Google Scholar
• Peñaloza HF, Alvarez D, Muñoz‐Durango N, et al. The role of myeloid‐derived suppressor cells in chronic infectious diseases and the current methodology available for their study. J Leukoc Biol. 2019;105(5):857–872.
   PubMed Web of Science ®Google Scholar
• Damuzzo V, Pinton L, Desantis G, et al. Complexity and challenges in defining myeloid‐derived suppressor cells. Cytometry. 2014;88(2):n/a– 91.
   Google Scholar
• Youn JI, Collazo M, Shalova IN, et al. Characterization of the nature of granulocytic myeloid‐derived suppressor cells in tumor‐bearing mice. J Leukoc Biol. 2012;91(1):167–181.
   PubMed Web of Science ®Google Scholar
• Yang J, Zhang L, Yu C, et al. Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases. Biomark Res. 2014;2(1):1.
   PubMedGoogle Scholar
• Mandruzzato S, Brandau S, Britten CM, et al. Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study. Cancer Immunol Immunother. 2016;65(2):161–169.
   PubMed Web of Science ®Google Scholar
• Condamine T, Dominguez GA, Youn J-I, et al. Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci Immunol. 2016;1(2):aaf8943.
   PubMed Web of Science ®Google Scholar
• Bronte V, Brandau S, Chen S-H, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7(1):12150.
   PubMed Web of Science ®Google Scholar
• Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 2011;32(1):19–25.
   PubMed Web of Science ®Google Scholar
• Dolcetti L, Peranzoni E, Ugel S, et al. Hierarchy of immunosuppressive strength among myeloid‐derived suppressor cell subsets is determined by GM‐CSF. Eur J Immunol. 2009;40(1):22–35.
   Web of Science ®Google Scholar
• Condamine T, Mastio J, Gabrilovich DI. Transcriptional regulation of myeloid‐derived suppressor cells. J Leukoc Biol. 2015;98(6):913–922.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sica A, Allavena P, et al. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol. 2009;70(5):325–330.
   PubMed Web of Science ®Google Scholar
• Ribechini E, Hutchinson JA, Hergovits S, et al. Novel GM-CSF signals via IFN-γR/IRF-1 and AKT/mTOR license monocytes for suppressor function. Blood Adv. 2017;1(14):947–960.
   PubMed Web of Science ®Google Scholar
• Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol. 2018;19(2):108–119.
   PubMed Web of Science ®Google Scholar
• Cheng P, Kumar V, Liu H, et al. Effects of notch signaling on regulation of myeloid cell differentiation in cancer. Cancer Res. 2014;74(1):141–152.
   PubMed Web of Science ®Google Scholar
• Ostrand-Rosenberg S, Fenselau C. Myeloid-derived suppressor cells: immune-suppressive cells that impair antitumor immunity and are sculpted by their environment. J Immunol. 2018;200(2):422–431.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162.
   PubMed Web of Science ®Google Scholar
• Nefedova Y, Huang M, Kusmartsev S, et al. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol. 2004;172(1):464–474.
   PubMed Web of Science ®Google Scholar
• Rébé C, Végran F, Berger H, et al. STAT3 activation: a key factor in tumor immunoescape. Jak-stat. 2013;2(1):e23010.
   PubMedGoogle Scholar
• Nefedova Y, Nagaraj S, Rosenbauer A, et al. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res. 2005;65(20):9525–9535.
   PubMed Web of Science ®Google Scholar
• Xin H, Zhang C, Herrmann A, et al. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 2009;69(6):2506.
   PubMed Web of Science ®Google Scholar
• Cheng P, Corzo CA, Luetteke N, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med. 2008;205(10):2235–2249.
   PubMed Web of Science ®Google Scholar
• Sinha P, Okoro C, Foell D, et al. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol. 2008;181(7):4666–4675.
   PubMed Web of Science ®Google Scholar
• Gebhardt C, Németh J, Angel P, et al. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol. 2006;72(11):1622–1631.
   PubMed Web of Science ®Google Scholar
• Stewart TJ, Greeneltch KM, Reid JE, et al. Interferon regulatory factor‐8 modulates the development of tumour‐induced CD11b + Gr‐1+ myeloid cells. J Cell Mol Med. 2009;13(9b):3939–3950.
   PubMed Web of Science ®Google Scholar
• Waight JD, Netherby C, Hensen ML, et al. Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. J Clin Invest. 2013;123(10):4464–4478.
   PubMed Web of Science ®Google Scholar
• Netherby CS, Abrams SI. Mechanisms overseeing myeloid-derived suppressor cell production in neoplastic disease. Cancer Immunol Immunother. 2017;66(8):989–996.
   PubMed Web of Science ®Google Scholar
• Netherby CS, Messmer MN, Burkard-Mandel L, et al. The granulocyte progenitor stage is a key target of IRF8-mediated regulation of myeloid-derived suppressor cell production. J Immunol. 2017;198(10):4129–4139.
   PubMed Web of Science ®Google Scholar
• Liu Y, Xiang X, Zhuang X, et al. Contribution of MyD88 to the tumor exosome-mediated induction of myeloid derived suppressor cells. Am J Pathol. 2010;176(5):2490–2499.
   PubMed Web of Science ®Google Scholar
• Delano MJ, Scumpia PO, Weinstein JS, Coco D, et al. MyD88-dependent expansion of an immature GR-1+ CD11b + population induces T cell suppression and Th2 polarization in sepsis. J Exp Med. 2007;204(6):1463–1474.
   PubMed Web of Science ®Google Scholar
• Marigo I, Bosio E, Solito S, et al. Tumor-induced tolerance and immune suppression depend on the C/EBPβ transcription factor. Immunity. 2010;32(6):790–802.
   PubMed Web of Science ®Google Scholar
• Thevenot PT, Sierra RA, Raber PL, et al. The stress-response sensor chop regulates the function and accumulation of myeloid-derived suppressor cells in tumors. Immunity. 2014;41(3):389–401.
   PubMed Web of Science ®Google Scholar
• Sinha P, Clements VK, Fulton AM, et al. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 2007;67(9):4507–4513.
   PubMed Web of Science ®Google Scholar
• Talmadge JE, Hood KC, Zobel LC, et al. Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion. Int immunopharmacol. 2007;7(2):140–151.
   PubMed Web of Science ®Google Scholar
• Mao Y, Poschke I, Wennerberg E, de Coaña YP, et al. Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2–dependent mechanisms. Cancer Res. 2013;73(13):3877.
   PubMed Web of Science ®Google Scholar
• Mao Y, Sarhan D, Steven A, et al. Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity. Clin Cancer Res. 2014;20(15):4096.
   PubMed Web of Science ®Google Scholar
• Li J, Sun J, Rong R, et al. HMGB1 promotes myeloid-derived suppressor cells and renal cell carcinoma immune escape. Oncotarget. 2017;8(38):63290.
   PubMedGoogle Scholar
• Kaiser J, Couzin-Frankel J. Cancer immunotherapy sweeps Nobel for medicine. Science. 2018;362(6410):13.
   PubMed Web of Science ®Google Scholar
• Nam S, Lee A, Lim J, et al. Analysis of the expression and regulation of PD-1 protein on the surface of myeloid-derived suppressor cells (MDSCs). Biomol Ther. 2019;27(1):63.
   PubMed Web of Science ®Google Scholar
• Dong G, Yao X, Yan F, et al. Ligation of CD180 contributes to endotoxic shock by regulating the accumulation and immunosuppressive activity of myeloid-derived suppressor cells through STAT3. Biochim Biophys Acta Mol Basis Dis. 2019;1865(3):535–546.
   PubMed Web of Science ®Google Scholar
• Corzo CA, Cotter MJ, Cheng P, et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol. 2009;182(9):5693–5701.
   PubMed Web of Science ®Google Scholar
• Lu T, Ramakrishnan R, Altiok S, et al. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest. 2011;121(10):4015–4029.
   PubMed Web of Science ®Google Scholar
• Nagaraj S, Gupta K, Pisarev V, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007;13(7):828.
   PubMed Web of Science ®Google Scholar
• Sade-Feldman M, Kanterman J, Ish-Shalom E, et al. Tumor necrosis factor-α blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity. 2013;38(3):541–554.
   PubMed Web of Science ®Google Scholar
• Lee B-R, Chang S-Y, Hong E-H, et al. Elevated endoplasmic reticulum stress reinforced immunosuppression in the tumor microenvironment via myeloid-derived suppressor cells. Oncotarget. 2014;5(23):12331.
   PubMedGoogle Scholar
• Condamine T, Kumar V, Ramachandran IR, et al. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R–mediated apoptosis. J Clin Invest. 2014;124(6):2626–2639.
   PubMed Web of Science ®Google Scholar
• Sahakian E, Powers JJ, Chen J, et al. Histone deacetylase 11: a novel epigenetic regulator of myeloid derived suppressor cell expansion and function. Mol Immunol. 2015;63(2):579–585.
   PubMed Web of Science ®Google Scholar
• Gabitass RF, Annels NE, Stocken DD, et al. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother. 2011;60(10):1419.
   PubMed Web of Science ®Google Scholar
• Highfill SL, Rodriguez PC, Zhou Q, et al. Bone marrow myeloid-derived suppressor cells (MDSC) inhibit graft-versus-host (GVHD) disease via an arginase-1 dependent mechanism that is upregulated by IL-13. Blood. 2010;116(25):5738–5747.
   PubMed Web of Science ®Google Scholar
• Greifenberg V, Ribechini E, Rößner S, et al. Myeloid‐derived suppressor cell activation by combined LPS and IFN‐γ treatment impairs DC development. Eur J Immunol. 2009;39(10):2865–2876.
   PubMed Web of Science ®Google Scholar
• Rodriguez PC, Hernandez CP, Quiceno D, et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med. 2005;202(7):931–939.
   PubMed Web of Science ®Google Scholar
• Tu S, Bhagat G, Cui G, et al. Overexpression of interleukin-1β induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer cell. 2008;14(5):408–419.
   PubMed Web of Science ®Google Scholar
• He D, Li H, Yusuf N, et al. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol. 2010;184(5):2281. ji_0902574.
   PubMed Web of Science ®Google Scholar
• Markiewski MM, DeAngelis RA, Benencia F, et al. Modulation of the antitumor immune response by complement. Nat Immunol. 2008;9(11):1225.
   PubMed Web of Science ®Google Scholar
• Parker KH, Sinha P, Horn LA, et al. HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells. Cancer Res. 2014;74(20):5723.
   PubMed Web of Science ®Google Scholar
• Sikalidis AK. Amino acids and immune response: a role for cysteine, glutamine, phenylalanine, tryptophan and arginine in T-cell function and cancer? Pathol Oncol Res. 2015;21(1):9–17.
   PubMed Web of Science ®Google Scholar
• Wu H, Zhen Y, Ma Z, et al. Arginase-1–dependent promotion of TH17 differentiation and disease progression by MDSCs in systemic lupus erythematosus. Sci Transl Med. 2016;8(331):331ra40–331ra40.
   PubMed Web of Science ®Google Scholar
• Srivastava MK, Sinha P, Clements VK, et al. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 2009;70(1):68–77.
   PubMed Web of Science ®Google Scholar
• Yu J, Du W, Yan F, et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol. 2013;190(7):3783–3797.
   PubMed Web of Science ®Google Scholar
• Greten TF, Manns MP, Korangy F. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol. 2011;11(7):802–807.
   PubMed Web of Science ®Google Scholar
• Hanson EM, Clements VK, Sinha P, et al. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J Immunol. 2009;183(2):937.
   PubMed Web of Science ®Google Scholar
• Arbonés ML, Ord DC, Ley K, et al. Lymphocyte homing and leukocyte rolling and migration are impaired in L-selectin-deficient mice. Immunity. 1994;1(4):247–260.
   PubMed Web of Science ®Google Scholar
• Serafini P, Mgebroff S, Noonan K, et al. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 2008;68(13):5439–5449.
   PubMed Web of Science ®Google Scholar
• Lindau D, Gielen P, Kroesen M, et al. The immunosuppressive tumour network: myeloid‐derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 2013;138(2):105–115.
   PubMed Web of Science ®Google Scholar
• Li H, Han Y, Guo Q, et al. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-β1. J Immunol. 2009;182(1):240–249.
   PubMed Web of Science ®Google Scholar
• Ioannou M, Alissafi T, Lazaridis I, et al. Crucial role of granulocytic myeloid-derived suppressor cells in the regulation of central nervous system autoimmune disease. J Immunol. 2011;188(3):1136–1146.
   PubMed Web of Science ®Google Scholar
• King IL, Dickendesher TL, Segal BM. Circulating Ly-6C + myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. Blood. 2009;113(14):3190–3197.
   PubMed Web of Science ®Google Scholar
• Yi H, Guo C, Yu X, et al. Mouse CD11b + Gr-1+ myeloid cells can promote Th17 cell differentiation and experimental autoimmune encephalomyelitis. J Immunol. 2012;189(9):4295–4304.
   PubMed Web of Science ®Google Scholar
• Zhu B, Bando Y, Xiao S, et al. CD11b + Ly-6Chi suppressive monocytes in experimental autoimmune encephalomyelitis. J Immunol. 2007;179(8):5228–5237.
   PubMed Web of Science ®Google Scholar
• Haile LA, Von Wasielewski R, Gamrekelashvili J, et al. Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. Gastroenterology. 2008;135(3):871.e5–881.e5.
   Web of Science ®Google Scholar
• Kerr EC, Raveney BJ, Copland DA, Dick AD, et al. Analysis of retinal cellular infiltrate in experimental autoimmune uveoretinitis reveals multiple regulatory cell populations. J Autoimmun. 2008;31(4):354–361.
   PubMed Web of Science ®Google Scholar
• Marhaba R, Vitacolonna M, Hildebrand D, et al. The importance of myeloid-derived suppressor cells in the regulation of autoimmune effector cells by a chronic contact eczema. J Immunol. 2007;179(8):5071–5081.
   PubMed Web of Science ®Google Scholar
• Liu Y-F, Zhuang K-h, Chen B, et al. Expansion and activation of monocytic-myeloid-derived suppressor cell via STAT3/arginase-I signaling in patients with ankylosing spondylitis. Arthritis Res Ther. 2018;20(1):168.
   PubMed Web of Science ®Google Scholar
• Yin B, Ma G, Yen C-Y, et al. Myeloid-derived suppressor cells prevent type 1 diabetes in murine models. J Immunol. 2010;185(10):5828–5834.
   PubMed Web of Science ®Google Scholar
• Cripps JG, Wang J, Maria A, et al. Type 1 T helper cells induce the accumulation of myeloid‐derived suppressor cells in the inflamed Tgfb1 knockout mouse liver. Hepatology. 2010;52(4):1350–1359.
   PubMed Web of Science ®Google Scholar
• Zuo D, Yu X, Guo C, et al. Scavenger receptor a restrains T‐cell activation and protects against concanavalin A‐induced hepatic injury. Hepatology. 2013;57(1):228–238.
   PubMed Web of Science ®Google Scholar
• Fujii W, Ashihara E, Hirai H, et al. Myeloid-derived suppressor cells play crucial roles in the regulation of mouse collagen-induced arthritis. J Immunol. 2013;191(3):1073–1083.
   PubMed Web of Science ®Google Scholar
• Park M-J, Lee S-H, Kim E-K, et al. Interleukin-10 produced by myeloid-derived suppressor cells is critical for the induction of Tregs and attenuation of rheumatoid inflammation in mice. Sci Rep. 2018;8(1):3753.
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang S, Huang Y, et al. Myeloid-derived suppressor cells are proinflammatory and regulate collagen-induced arthritis through manipulating Th17 cell differentiation. Clin Immunol. 2015;157(2):175–186.
   PubMed Web of Science ®Google Scholar
• Guo C, Hu F, Yi H, et al. Myeloid-derived suppressor cells have a proinflammatory role in the pathogenesis of autoimmune arthritis. Ann Rheum Dis. 2014;75(1):278–285.
   PubMed Web of Science ®Google Scholar
• Egelston C, Kurkó J, Besenyei T, Tryniszewska B, et al. Suppression of dendritic cell maturation and T cell proliferation by synovial fluid myeloid cells from mice with autoimmune arthritis. Arthritis Rheum. 2012;64(10):3179–3188.
   PubMed Web of Science ®Google Scholar
• Romas E, Gillespie M, Martin T. Involvement of receptor activator of NFκB ligand and tumor necrosis factor-α in bone destruction in rheumatoid arthritis. Bone. 2002;30(2):340–346.
   PubMed Web of Science ®Google Scholar
• Zhao X, Rong L, Zhao X, et al. TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Invest. 2012;122(11):4094–4104.
   PubMed Web of Science ®Google Scholar
• Cornish AL, Campbell IK, McKenzie BS, et al. G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol. 2009;5(10):554.
   PubMed Web of Science ®Google Scholar
• Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423(6937):356.
   PubMed Web of Science ®Google Scholar
• Kleinewietfeld M, Hafler DA. The plasticity of human Treg and Th17 cells and its role in autoimmunity. Semin Immunol. 2013;25(4):305–312.
   PubMed Web of Science ®Google Scholar
• Kurkó J, Vida A, Glant TT, et al. Identification of myeloid-derived suppressor cells in the synovial fluid of patients with rheumatoid arthritis: a pilot study. BMC Musculoskelet Disord. 2014;15(1):281.
   PubMed Web of Science ®Google Scholar